Shigellosis Clinical Trial
Official title:
Safety and Reactogenicity of a Candidate Vaccine Against S. Dysenteriae When Administered to Healthy Adults
Healthy volunteers will receive a 2-dose vaccination with Shigella dysenteriae candidate vaccine spaced 8 weeks apart. The objective is to demonstrate the safety and reactogenicity of the Shigella dysenteriae bioconjugate vaccine (GVXN SD133) alone or in combination with an adjuvant (Aluminium Hydroxide). The safety and reactogenicity of the GVXN SD133 vaccine will be also evaluated at two different concentrations of antigen, Shigella polysaccharide O1. Blood samples will be collected at intervals to examine systemic vaccine antigen-specific immune responses.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02797236 -
SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers
|
Phase 1 | |
| Completed |
NCT04056117 -
A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05959616 -
Shigella Sonnei 53G Human Infection Study in Kenyan Adults
|
Phase 1 | |
| Completed |
NCT02445963 -
Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR)
|
Phase 1 | |
| Not yet recruiting |
NCT05961059 -
InvaplexAR-Detox and dmLT Adjuvant in the Netherlands and Zambia
|
Phase 1 | |
| Completed |
NCT00485134 -
Shigella Flexneri 2a Invaplex 50 Vaccine Dose Finding and Assessment of Protection
|
Phase 1/Phase 2 | |
| Completed |
NCT01369927 -
Shigella Sonnel O-SPC/rBRU Conjugate Vaccine
|
Phase 1 | |
| Completed |
NCT02034500 -
Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults
|
Phase 1 | |
| Completed |
NCT01509846 -
Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults
|
Phase 1 | |
| Completed |
NCT02105714 -
Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders
|
N/A | |
| Withdrawn |
NCT01399424 -
Shigella Sonnei OSPC-rDT Conjugate Vaccine
|
Phase 1 | |
| Completed |
NCT00800930 -
Therapeutic Induction of Endogenous Antibiotics
|
Phase 2 | |
| Completed |
NCT00368316 -
Safety, Immunogenicity and Efficacy of Shigella Conjugate Vaccines in 1-4 Year Olds in Israel
|
Phase 3 | |
| Recruiting |
NCT05182749 -
Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis
|
Phase 1/Phase 2 | |
| Completed |
NCT02388009 -
Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a
|
Phase 1 | |
| Completed |
NCT02017899 -
A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.
|
Phase 1 | |
| Completed |
NCT02646371 -
Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a
|
Phase 2 | |
| Recruiting |
NCT05156528 -
Efficacy, Immunogenicity and Safety of S. Flexneriza-S. Sonnei Bivalent Conjugate Vaccine in Volunteers Aged From 6 Months to 5 Years
|
Phase 3 | |
| Completed |
NCT03854929 -
Ciprofloxacin Versus Azithromycin for Children Hospitalised With Dysentery
|
Phase 4 | |
| Recruiting |
NCT05121974 -
Tebipenem Trial in Children With Shigellosis
|
Phase 2 |